Cardiovascular Research-Translational Studies, Department of Clinical Sciences Malmö, Lund University, 205 02 Malmö, Sweden.
Department of Cardiology, Skåne University Hospital, 205 02 Malmö, Sweden.
Int J Mol Sci. 2024 May 29;25(11):5911. doi: 10.3390/ijms25115911.
There is a lack of studies aiming to assess cellular a disintegrin and metalloproteinase-17 (ADAM-17) activity in COVID-19 patients and the eventual associations with the shedding of membrane-bound angiotensin-converting enzyme 2 (mACE2). In addition, studies that investigate the relationship between ACE2 and ADAM-17 gene expressions in organs infected by SARS-CoV-2 are lacking. We used data from the Massachusetts general hospital COVID-19 study (306 COVID-19 patients and 78 symptomatic controls) to investigate the association between plasma levels of 33 different ADAM-17 substrates and COVID-19 severity and mortality. As a surrogate of cellular ADAM-17 activity, an ADAM-17 substrate score was calculated. The associations between soluble ACE2 (sACE2) and the ADAM-17 substrate score, renin, key inflammatory markers, and lung injury markers were investigated. Furthermore, we used data from the Genotype-Tissue Expression (GTEx) database to evaluate and gene expressions by age and sex in ages between 20-80 years. We found that increased ADAM-17 activity, as estimated by the ADAM-17 substrates score, was associated with COVID-19 severity ( = 0.001). ADAM-17 activity was also associated with increased mortality but did not reach statistical significance ( = 0.06). Soluble ACE2 showed the strongest positive correlation with the ADAM-17 substrate score, follow by renin, interleukin-6, and lung injury biomarkers. The ratio of to gene expression was highest in the lung. This study indicates that increased ADAM-17 activity is associated with severe COVID-19. Our findings also indicate that there may a bidirectional relationship between membrane-bound ACE2 shedding via increased ADAM-17 activity, dysregulated renin-angiotensin system (RAS) and immune signaling. Additionally, differences in and gene expressions between different tissues may be of importance in explaining why the lung is the organ most severely affected by COVID-19, but this requires further evaluation in prospective studies.
目前缺乏评估 COVID-19 患者细胞解整合素金属蛋白酶 17(ADAM-17)活性的研究,也缺乏最终与膜结合血管紧张素转化酶 2(mACE2)脱落相关的研究。此外,目前也缺乏研究调查感染 SARS-CoV-2 的器官中 ACE2 和 ADAM-17 基因表达之间的关系。我们使用来自马萨诸塞州综合医院 COVID-19 研究(306 例 COVID-19 患者和 78 例有症状对照者)的数据,来调查血浆中 33 种不同 ADAM-17 底物与 COVID-19 严重程度和死亡率之间的关系。作为细胞 ADAM-17 活性的替代物,我们计算了 ADAM-17 底物评分。我们还研究了可溶性 ACE2(sACE2)与 ADAM-17 底物评分、肾素、关键炎症标志物和肺损伤标志物之间的关系。此外,我们使用来自基因型组织表达(GTEx)数据库的数据,按年龄和性别评估了 20-80 岁年龄组的 和 基因表达。我们发现,ADAM-17 底物评分估计的 ADAM-17 活性增加与 COVID-19 严重程度相关( = 0.001)。ADAM-17 活性也与死亡率增加相关,但未达到统计学意义( = 0.06)。可溶性 ACE2 与 ADAM-17 底物评分的相关性最强,其次是肾素、白细胞介素 6 和肺损伤生物标志物。肺中 与 基因表达的比值最高。这项研究表明,ADAM-17 活性增加与严重的 COVID-19 相关。我们的研究结果还表明,通过增加 ADAM-17 活性导致的膜结合 ACE2 脱落与失调的肾素-血管紧张素系统(RAS)和免疫信号之间可能存在双向关系。此外,不同组织中 与 基因表达的差异可能对解释为什么肺是受 COVID-19 影响最严重的器官具有重要意义,但这需要在前瞻性研究中进一步评估。